Sensus Healthcare, Inc.

Good day and welcome to the Census Healthcare fourth quarter 2024 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your touch-tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Tirth Patel, Alliance Advisors IR. Please go ahead.

Good afternoon. This is Tirth Patel with Alliance Advisors IR. Thank you all for joining today's call to discuss Census Healthcare's fourth quarter and full year 2024 financial results. Joining me from Census are Joe Cerdano, Chairman and Chief Executive Officer, Michael Cerdano, President and General Counsel, and Javier Rimpolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activity since it's healthcare assumes, plans, expects, believes, intends, or anticipates, and other similar expressions will, should, or may occur in the future are forward-looking statements. The forward-looking statements are management's beliefs based upon currently available information as of the date of this conference call, February 5th, 2025. Census Healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's forms 10-K, 10-Q, and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Census believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results press release. With that, I'd like to turn the call over to Joe Sardano. Joe.

Thank you, Terry. Good afternoon, everyone, and thank you for joining us today. Reflecting on our performance over the past year, Census Healthcare experienced strong business momentum as we continue to expand our customer base, refine our product offering, and reinforce our company's position as a leader in superficial radiotherapy. Top line results demonstrate the market's growing acceptance of our SRT100 platforms, especially in dermatology practices that value non-surgical treatment options for non-melanoma skin cancer and keloids. I'd like to start by highlighting our major accomplishments. We've built upon many of the themes I've discussed throughout the year, specifically strong execution of our sales strategy, expansion of our Fair Deal Agreement program, and ongoing enhancements to our research and development pipeline. The Fair Deal Agreement, or FDA-initiated initiative, has gained significant traction over the past year and is evolving into an important strategic growth driver. particularly for large dermatology groups and private equity-backed practices looking for both clinical value and financial flexibility. During our sales calls, we emphasized the importance of delivering solutions that align with customer goals, and we continue to see heightened enthusiasm for agreements with Attractive Economics. Overall, our focused strategy and ongoing innovations are driving the results we're reporting today. I'm proud of our team's execution and look forward to capitalizing on new opportunities in 2025. From a financial perspective, I'm pleased to report that our fourth quarter performance capped an outstanding year. We recorded revenue of $13.1 million for the quarter and $41.8 million for the year, which is up 71% compared to 2023. These results reflect higher unit sales of our flagship SRT100 systems driven by expanding clinical awareness and broadening reimbursement for superficial radiation therapy. We delivered a quarterly record of 39 systems in the fourth quarter and 115 for the full year, increases of 18% and 74% respectively. It's important to note that within these shipments, five were to international customers in the quarter and 10 were shipped internationally during the year. advancing the approach we outlined in our Q2 call. We continue to deepen relationships with established distributors and prospective partners across multiple geographies where there remains significant unmet need for non-invasive treatment options. Profitability remains central to our strategy, and I'm proud to share that we achieved our fifth consecutive quarter of profitability with net income of $1.4 million for the quarter. We also ended the year with $22.1 million in cash and cash equivalents with no debt, reflecting our ability to maintain a strong capital position. We believe this level of liquidity provides the flexibility to support ongoing R&D, fund potential partnership opportunities, and further invest in sales and marketing initiatives that will drive the company's next phase of growth. I would like now to turn the call over to Michael to discuss the growth trajectory for our FDA program and other upcoming strategic goals. Michael.